Physician profile
Sharon Cote
NPI 1932173812
$3,113.40
in general payments reported to CMS, 2019-2025
30 companies · $99.94 in 2025
The $99.94 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $175 · 2021: $204 · 2022: $731 · 2023: $709 · 2024: $472 · 2025: $99.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.20 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $364.30 | 2023-2024 | |
| Daiichi Sankyo INC. | $340.25 | 2019-2024 | Injectafer |
| Hologic Sales and Service, LLC | $266.09 | 2019-2025 | Thinprep 2000 Processor, Fluent Fluid Management System |
| Allergan, INC. | $212.24 | 2019-2020 | |
| Myovant Sciences INC. | $147.97 | 2021-2022 | |
| Astellas Pharma US INC | $141.61 | 2019-2025 | Veozah |
| Organon LLC | $139.40 | 2021-2025 | Nexplanon |
| Baxter Healthcare | $128.79 | 2019 | |
| Sumitomo Pharma America, INC. | $111.82 | 2023 | Myfembree |
| Merck Sharp & Dohme LLC | $111.17 | 2019-2024 | Gardasil 9, Gardasil |
| Exeltis, USA INC. | $104.00 | 2020-2024 | Slynd |
| Pfizer INC. | $86.07 | 2019-2025 | |
| Scynexis, INC. | $83.82 | 2022 | |
| Biogen, INC. | $67.55 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $61.50 | 2022-2024 | |
| Therapeuticsmd, INC. | $56.36 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $45.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.30 | 2022-2023 | |
| Avanos Medical | $22.65 | 2019 | |
| Covidien LP | $22.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.83 | 2022 | |
| Shield Therapeutics INC | $21.55 | 2023 | Accrufer |
| Coopersurgical, INC. | $20.97 | 2024 | Paragard T 380a |
| Exact Sciences Corporation | $18.94 | 2023 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $17.50 | 2020 | |
| Duchesnay USA Incorporated | $16.11 | 2019 | |
| Avion Pharmaceuticals | $14.82 | 2019 | |
| Lilly USA, LLC | $13.49 | 2022 | |
| Agile Therapeutics, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Cote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.